{"id":"ancitabine","rwe":[],"tags":[{"label":"ancitabine","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Active","category":"status"},{"label":"Antimetabolites","category":"pharmacology"},{"label":"Antimetabolites, Antineoplastic","category":"pharmacology"},{"label":"Antineoplastic Agents","category":"pharmacology"},{"label":"Noxae","category":"pharmacology"}],"phase":"phase_2","safety":{"commonSideEffects":[]},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"ancytabine","offLabel":[],"synonyms":["ancitabine","ancytabine","cyclocytidine"],"timeline":[],"brandName":"Ancytabine","ecosystem":[],"mechanism":{"modality":"Small Molecule","drugClass":"ancitabine","explanation":"Imagine your body's cells are like factories that make copies of themselves. Ancytabine is a special molecule that gets inside these factories and blocks the machines that make new copies, preventing the cancer cells from growing and dividing.","oneSentence":"Ancytabine is a nucleoside analog that works by inhibiting DNA synthesis, thereby preventing cancer cell growth.","technicalDetail":"Ancytabine is a nucleoside analog that acts as a chain terminator in DNA synthesis, incorporating into DNA and preventing further elongation of the DNA chain, thereby inhibiting cancer cell growth."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/212","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=ANCITABINE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T08:47:33.654676","biosimilars":[],"competitors":[],"genericName":"ancitabine","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"DO2D32W0VC","CHEBI":"CHEBI:74838","INN_ID":"3992","UMLSCUI":"C0010557","ChEMBL_ID":"CHEMBL1412614","PUBCHEM_CID":"25051","MESH_DESCRIPTOR_UI":"D003504"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":0,"therapeuticAreas":["Oncology"],"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ancytabine (ANCITABINE) is a small molecule drug in the ancitabine class, originally developed by an unknown entity and currently owned by an unknown entity. Its target and exact mechanism of action are unknown. Ancytabine has not been approved by the FDA for any indications. Its commercial status, half-life, bioavailability, generic manufacturers, and off-patent status are also unknown. As a result, there is limited information available on this compound.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":false,"score":1}}